Familial B-cell Lymphoproliferative Disorders

Chronic Lymphocytic Leukemia Clinical Trial

— Familial_LPD  

Official title:

Epidemiology of Familial B-cell Lymphoproliferative Disorders

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05718986
• Other study ID #: FamilialLPD
• Status: Not yet recruiting
• Start date: June 2024
• Est. completion date: December 2040

Study information

• Verified date: May 2024
• Source: University of Haifa
• Contact: Geffen Kleinstern, PhD
• Phone: +972545715624
• Email: gkleinste[@]univ.haifa.ac.il
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This study investigates families with at least two cases of B-cell lymphoproliferative disorders (LPD), and evaluates the prevalence of LPD in families, the relationship between medical history, genetic factors, and the risk of familial LPD, and various clinical outcomes for these families in a multiethnic population of Jews and Arabs in Israel.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1000
• Est. completion date: December 2040
• Est. primary completion date: December 2028
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient inclusion criteria:

Patients must have LPD and must have a family history of LPD. LPD patients who signed an informed consent to participate in the study. Criteria for the inclusion of relatives of patients: Relatives must be related by blood to LPD patients or unrelated (for control group). Relatives who signed an informed consent to participate in the study.

Exclusion Criteria:

• Pregnant women, special populations and those lacking judgment will not be included

Related Conditions & MeSH terms

• Chronic Lymphocytic Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid
• Lymphocytosis
• Lymphoproliferative Disorders
• Monoclonal B-Cell Lymphocytosis
• Precancerous Conditions

Intervention

Other:
• No intervention
No intervention

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
University of Haifa	Bnai Zion Medical Center

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of familial LPD in Israel		5 years
Primary	Association between medical history and genetic variants and the risk of familial LPD		5 years
Primary	Risk of clinical outcomes among familial LPD and family members		15 years